<DOC>
	<DOCNO>NCT02350309</DOCNO>
	<brief_summary>This single-dose , randomize , placebo-controlled , 3-way crossover study 2 dosage strength E2006 ( 5 mg 10 mg ) subject insomnia disorder .</brief_summary>
	<brief_title>Study Evaluate Effect 2 Dosage Strengths E2006 Multiple Sleep Latency Test Subjects With Insomnia Disorder</brief_title>
	<detailed_description>The study 2 phase : Prerandomization Randomization . The Prerandomization Phase consist 2 period take together , last maximum 21 day : Screening Period Baseline Period . The Randomization Phase comprise 4 treatment period ( Treatment 1 , Treatment 2 , Treatment 3 , Treatment 4 ) intervene washout period treatment period ( Washout 1 , Washout 2 , Washout 3 ) . A single dose study drug administer randomize , 3-way double-blind crossover manner Treatment Periods 1-3 ; flurazepam 30 mg administer open-label manner Treatment Period 4 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Flurazepam</mesh_term>
	<criteria>1 . Male female , age 18 old , time informed consent . 2 . Meets 5th edition Diagnostic Statistical Manual Mental Disorders ( DSM5 ) criteria Insomnia Disorder , follow : 1 . Complains dissatisfaction nighttime sleep despite adequate opportunity sleep , complaint one following : difficulty get sleep , difficulty stay asleep , awaken earlier morning desire . 2 . Frequency complaint great equal 3 time per week . 3 . Duration complaint great equal 3 month . 4 . Associated complaint daytime impairment . 3 . Insomnia Severity Index score great equal 15 Screening . 4 . Regular time bed 7 9 hour report Screening . 5 . Regular bedtime , define time subject attempt fall asleep , 21:00 24:00 regular wake time 05:00 09:00 report Screening . 6 . Confirmation current insomnia symptom determine response Sleep Diary complete 7 night Screening , subject Sleep Onset Latency ( sSOL ) great equal 30 minute least 3 night subjective Wake After Sleep Onset ( sWASO ) great equal 60 minute least 3 night . 1 . Excessive morning sleepiness Baseline determine average SOL Baseline le 10 minute . 2 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ betahCG ] human chorionic gonadotropin [ hCG ] test minimum sensitivity 25 IU/L equivalent unit betahCG hCG ) . ( Note : A negative urine pregnancy test require checkin dose study drug flurazepam ) . 3 . If female childbearing potential : 1 . Had unprotected sexual intercourse within 30 day study entry agree use highly effective method contraception ( eg , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 28 day study drug discontinuation . 2 . Are currently abstinent , agree use double barrier method ( describe ) refrain sexual activity study period 28 day study drug discontinuation . 3 . Are use hormonal contraceptive stable dose hormonal contraceptive product least 4 week dose agree use contraceptive study 28 day study drug discontinuation . NOTE : All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . 4 . A current diagnosis sleeprelated breathe disorder , periodic limb movement disorder , restless legs syndrome , circadian rhythm sleep disorder , narcolepsy , exclusionary score screen instrument rule individual symptom certain sleep disorder insomnia . 5 . Reports experience within past year confusional arousal , symptom REM Behavior Disorder , sleeprelated violent behavior Munich Parasomnia Scale ( MUPS ) , history aberrant nocturnal behavior include sleepdriving sleepeating . 6 . Habitually nap 3 time per week . 7 . History drug alcohol dependency abuse within approximately last 2 year . 8 . Has positive drug screen Screening . 9 . A prolonged QT/QTc interval ( QTc great 450 m ) demonstrate repeat ECG Screening ( repeat initial ECG indicate QTc interval great 450 m ) . 10 . Any suicidal ideation intent without plan Screening within 6 month Screening lifetime suicidal behavior . 11 . Evidence clinically significant disease ( eg , cardiac , respiratory , gastrointestinal , renal , psychiatric neurological disease , chronic pain ) opinion investigator ( ) could affect subject 's safety interfere study assessment . 12 . Used prohibited prescription overthecounter concomitant medication within 2 week prior Screening , Screening Randomization . 13 . Used modality treatment insomnia , include cognitive behavioral therapy marijuana within 2 week prior Screening , Screening Randomization . 14 . Scheduled surgery study . 15 . Transmeridian travel across 3 time zone 2 week Screening , Screening Baseline , plan travel 3 time zone study . 16 . Hypersensitivity flurazepam , study drug , excipients . 17 . Currently enrol another clinical trial use investigational drug device within 28 day 5 x halflife , whichever longer precede informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Insomnia Disorder</keyword>
	<keyword>E2006</keyword>
	<keyword>Multiple Sleep Latency Test</keyword>
</DOC>